By PPN News Staff
The FDA updated the emergency use authorization (EUA) for Regeneron’s Regen-Cov, lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab), which is half the dose originally authorized.
As part of the updated EUA, casirivimab-imdevimab should be administered by IV infusion; subcutaneous injections are an alternative when IV infusion is not feasible and would lead to a delay in treatment.